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Background 
Narcolepsy is a lifelong debilitating condition caused by hypocretin deficiency [1] with symptoms 
including excessive sleep disorder. In idiopathic narcolepsy there is a highly selective loss of 85–95% 
of hypocretin producing hypothalamic neurons [2], and this has motivated multiple whole-brain voxel 
based morphometry (VBM) [3] studies exploring MRI detectable structural changes to the grey matter 
(GM) in narcolepsy. Findings are inconsistent, with some reporting multiple GM changes compared to 
healthy control subjects, for example [4], and others reporting none [5]. This inconsistency is not 
atypical of neuroimaging studies, where small numbers of subjects and experimental variability can 
produce results that are not generalizable [6]. This has driven the development of coordinate based 
meta-analysis (CBMA), which statistically combines the significant coordinates from multiple studies 
to distinguish study specific effects from grey matter alteration that is consistent across studies. The 
aim of meta-analysis is objective appraisal of evidence from multiple independent studies [7].  There 
are several CBMA algorithms available, but all have a similar approach. Using the coordinates of grey 
matter loss reported by VBM studies, a measure of spatial consistency of reporting across studies is 
computed on a voxel-wise basis. To assess statistical significance these measures are compared to 
those obtained when the coordinates are replaced by random coordinates. Therefore, after 
controlling for multiple voxel-wise statistical tests, significant results are indicative of stronger 
agreement across studies than expected by random chance.  
Weng et al [8] recently performed a CBMA of eight VBM studies of narcolepsy utilising the activation 
likelihood estimation (ALE) algorithm [9, 10]. This showed multiple regions of consistent GM loss 
including the hypothalamus. These results were subsequently demonstrated to be due to an 
implementation issue with the software [11], and re-analysis using a corrected version (GingerALE 
2.3.3) detected no consistent significant regional GM loss [12]. This reanalyses employed the false 
discovery rate (FDR) method of controlling the type 1 error [13], which is no longer the recommended 
option in GingerALE [14] and has been superseded [15]. This has prompted a second re-evaluation of 
the narcolepsy data by Zhong and colleagues [16] employing the signed differential mapping (SDM) 
CBMA algorithm [17, 18]. The results apparently reaffirm the initial assessment that there is a 
consistent pattern of grey matter loss in narcolepsy. However, while the criticism of the use of FDR by 
Zhong and colleagues may have some validity, the SDM algorithm employed instead offers no 
principled control of the type 1 error rate [19]. The method therefore provides no quantitative 
evidence that the results are truly significant given the very large number (2x105) of voxel-wise 
statistical tests, which is in contradiction to the aim of meta-analysis [7]. The aim of this commentary 
is to clarify this situation using the latest version of the ALE algorithm [15], which avoids the criticism 
of FDR and offers principled control of the family wise error (FWE) rate.  
Coordinate based meta-analysis of voxel based morphometry studies of 
narcolepsy 
Details of the VBM studies included in the original meta-analysis [8] are given in table 1; the 
coordinates are also available to download from the previous commentary [12]. There are 8 studies 
involving 149 subjects with narcolepsy and 162 healthy control subjects. A total of 72 coordinates of 
grey matter loss were reported by these studies. Only half of the studies used a principled method to 
control the type 1 error rate, while half used uncorrected p-values. 
Study Subjects with 
narcolepsy 
Healthy 
controls 
Reported 
coordinates 
Corrected 
statistics 
used 
[20] 29 29 4 
Courtesy of 
authors 
Yes 
[4] 12 32 19 No 
[5] 15 15 0 Yes 
[21] 12 12 2 Yes 
[22] 19 16 2 No 
[23] 17 17 29 No 
[24] 29 29 11 No 
[25] 16 12 5 Yes 
Table 1. Eight VBM studies of narcolepsy included in the CBMA. 
The data were subjected to a fourth analysis using the most recent type 1 error control scheme [15] 
implemented into GingerALE (version 2.3.6). An uncorrected p-value threshold of p<0001 was 
combined with a cluster-level FWE rate threshold of 005, and 1000 iterations were performed; these 
are the recommended settings.  
Results 
A single cluster (109 voxels) was detected indicating consistent regional GM atrophy of the 
hypothalamus, centred on Talairach coordinate (48, -09,-122) mm. Detection of this cluster invites 
closer inspection of the contributing studies for the purpose of validation and interpretation. The 
hypothalamic coordinate included in the Joo et al [24] study was not significant by whole-brain VBM 
but was included as a significant a-priori region of interest (ROI) result, it should therefore not have 
been included in the meta-analysis; ROI studies violate the assumptions of CBMA. Furthermore, the 
study by Buskova et al [22] is not a whole-brain VBM study, but rather an ROI study specifically of the 
hypothalamus in narcolepsy with cataplexy and should have also been excluded from the CBMA. 
Removing these coordinates eliminated the significant result detected by GingerALE.  
Summary and conclusion 
Coordinate based meta-analyses using the GingerALE software may not be valid if the version used 
pre-dates the fixes to the known implementation issues [11]. The impact can be considerable, as 
demonstrated by this reanalysis of the narcolepsy data using a fixed version of the software [12]. One 
limitation of the analysis was the use of FDR, which is no longer the recommended ALE method and 
has motivated a further reanalysis using SDM, which seemed to reaffirm the original findings. 
However, SDM has never been validated, instead an uncorrected p-value threshold was determined 
empirically from a single study on known positive data then assumed to be generally applicable [17]. 
This is not a safe assumption [19], and is the reason FDR and FWE methods are used. Consequently 
SDM provides no quantitative evidence that the results are critical of the null hypothesis. The 
presented third reanalysis overcomes all of the criticisms raised by using the cluster-level FWE control 
scheme with working implementation (version 2.3.6) of GingerALE [11], but found no evidence for 
spatially consistent effects reported by the 8 narcolepsy studies. 
These analyses all suffer from the limitations of the data. Eight (seven without the ROI study) studies 
are intuitively too few for reasonable statistical power, but the concept of power in CBMA is 
complicated by its explicit dependency on the specifics of the contributing studies. Nevertheless, a 
recent quantitative analysis of statistical power of the ALE algorithm [14] concluded that 20 studies 
are a minimum for typical effects (around 25% of studies reporting the effect), and that with just 7 
valid studies the estimated power is only around 20%. Indeed, with 7 studies the statistical power is 
such that only strong effects (most studies reporting coordinates in the same anatomical location) 
would be detectible by ALE, and these would be apparent by direct inspection of the studies. 
Furthermore, half of the studies used uncorrected p-value thresholds and some involved few subjects, 
which is known to greatly increase the risk of false positive results [6] that might have reduced the 
power to detect narcolepsy specific effects even further. Other limitations relate to the reporting of 
VBM studies, which can make it difficult to identify exactly what data to include. This resulted in the 
inclusion of a non-significant hypothalamic coordinate, which was reported [24] in a table that 
combined both whole-brain VBM and a-priori ROI results; ROI analyses are often reported alongside 
whole-brain analyses when there are a-priori regions of interest. Another study was presented as a 
VBM study throughout [22], but on careful reading turns out to be a region of interest study 
specifically of the hypothalamus. It is particularly important to avoid including ROI studies in CBMA as 
it biases the results and can erroneously reaffirm a-priori models of pathology.  This emphasizes the 
hurdles to performing a robust CBMA which necessitates: sufficient numbers of studies for reasonable 
statistical power to detect typical effects, close scrutiny of any studies contributing to significant 
clusters in CBMA to verify validity, and principled control of the type 1 error rate to provide 
quantitative evidence that the results are critical of the null hypothesis. 
In conclusion these meta-analyses provide no evidence of consistent regional grey matter atrophy 
specific to narcolepsy. However, given the limitations of the studies analysed, absence of significance 
is not suggestive that regional grey matter atrophy in narcolepsy is heterogeneous. 
Given the highlighted difficulties in selecting the valid coordinates for CBMA from each study, and in 
line with recommendations for scientific data analysis reporting [26], the coordinates used in this 
study are provided to allow further evaluation/validation. 
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